A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is
Mastalgia and fibrocystic breast disease is common in women. Ormeloxifene (SEVISTA) is a weak oestrogen receptor (ER) agonist, a strong ER antagonist (SERA) and therefore a selective ER modulator (SERM) used in the treatment of the disease. Aim of study was to see the efficacy of ormeloxifene in women with pain in breast associated with or without fibrocystic breast disease. Methods: This was a randomized control trial of oral ormeloxifene 30 mg alternate day for 3 month in patients of 20 -50doi:10.18203/2320-1770.ijrcog20150426 fatcat:vcwjbcnirbhn7njwgopypwjyyu